Oxford BioMedica PLC
LSE:OXB
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
166.8
445
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one OXB stock under the Base Case scenario is 718.92 GBX. Compared to the current market price of 412.5 GBX, Oxford BioMedica PLC is Undervalued by 43%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Oxford BioMedica PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for OXB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Oxford BioMedica PLC
Balance Sheet Decomposition
Oxford BioMedica PLC
Current Assets | 138.9m |
Cash & Short-Term Investments | 81.4m |
Receivables | 36.5m |
Other Current Assets | 21m |
Non-Current Assets | 106.1m |
PP&E | 71.6m |
Intangibles | 30m |
Other Non-Current Assets | 4.5m |
Current Liabilities | 59.1m |
Accounts Payable | 13m |
Accrued Liabilities | 13.9m |
Other Current Liabilities | 32.2m |
Non-Current Liabilities | 119.6m |
Long-Term Debt | 105.5m |
Other Non-Current Liabilities | 14.1m |
Earnings Waterfall
Oxford BioMedica PLC
Revenue
|
97.3m
GBP
|
Cost of Revenue
|
-61.5m
GBP
|
Gross Profit
|
35.7m
GBP
|
Operating Expenses
|
-102.7m
GBP
|
Operating Income
|
-67m
GBP
|
Other Expenses
|
-75m
GBP
|
Net Income
|
-142m
GBP
|
Free Cash Flow Analysis
Oxford BioMedica PLC
GBP | |
Free Cash Flow | GBP |
Oxford Biomedica had a transformative 2023, growing client orders from GBP 85 million to GBP 130 million while maintaining a strong cash balance of over GBP 100 million. Revenue grew from GBP 95 million to GBP 104 million by March, with 2024 revenue projected to rise by 40-50% to GBP 126-134 million. The company aims for breakeven in 2024, with long-term plans to double revenue by 2028. Cost reductions saved GBP 30 million annually. Minimal capital expenditures are planned, focusing on transferring platforms strategically without major new investments.
What is Earnings Call?
OXB Profitability Score
Profitability Due Diligence
Oxford BioMedica PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Oxford BioMedica PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
OXB Solvency Score
Solvency Due Diligence
Oxford BioMedica PLC's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Oxford BioMedica PLC's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OXB Price Targets Summary
Oxford BioMedica PLC
According to Wall Street analysts, the average 1-year price target for OXB is 489.73 GBX with a low forecast of 308.05 GBX and a high forecast of 777 GBX.
Dividends
Current shareholder yield for OXB is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
Contact
IPO
Employees
Officers
The intrinsic value of one OXB stock under the Base Case scenario is 718.92 GBX.
Compared to the current market price of 412.5 GBX, Oxford BioMedica PLC is Undervalued by 43%.